Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

（文章来源：证券日报） 证券日报网讯 1月14日，重药控股发布公告称，公司将于2026年1月19日召开2026年第一次临时股东 会。 ...

证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司会根据经营需要，探索设备 技术革新，合理降低物流成本。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司将根据业务发展需求，积极 引入先进生产力要素，优化物流环节，实现降本增效。 ...

Core Viewpoint - The announcement from the company indicates a conversion of bonds into shares, resulting in a slight dilution of the controlling shareholder's stake, which has decreased from 58.23% to 57.94% [1] Group 1 - The company announced that from January 10 to January 13, 2026, a total of 2,742,590 shares will be converted from "Yingte Convertible Bonds" [1] - The total share capital of the company will increase from 553,004,155 shares to 555,746,745 shares following the conversion [1] - As of January 13, the controlling shareholder, Zhejiang Provincial Pharmaceutical Health Industry Group Co., Ltd., and its concerted parties hold a total of 322,023,393 shares [1] Group 2 - The proportion of shares held by the controlling shareholder has decreased by 1% due to passive dilution [1] - All parties involved have experienced a passive decline in their shareholding ratios [1] - The changes do not involve any breach of commitments or violations [1]

Group 1 - The stock of Luyuan Pharmaceutical declined by 7.46% with a turnover rate of 28.29% and a trading volume of 2.835 billion yuan, experiencing a fluctuation of 19.68% throughout the day [2] - Institutional investors net bought 191 million yuan while brokerage seats collectively net sold 1.6723 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange's daily fluctuation board due to its 19.68% price change, with institutional special seats net buying 191 million yuan [2] Group 2 - The top five trading departments accounted for a total transaction of 559 million yuan, with a buying amount of 374 million yuan and a selling amount of 185 million yuan, resulting in a net buying of 189 million yuan [2] - Among the trading departments, four institutional special seats were present, with a total buying amount of 257 million yuan and a selling amount of 66.5 million yuan, leading to a net buying of 191 million yuan [2] - Over the past six months, the stock has appeared on the fluctuation board six times, with an average price increase of 4.26% the day after being listed and an average increase of 16.75% over the following five days [2] Group 3 - The stock experienced a net outflow of 238 million yuan in principal funds today, with a significant outflow of 146 million yuan from large orders and 9.207 million yuan from major orders [2] - In the past five days, the stock has seen a total net outflow of 770 million yuan in principal funds [2]

Core Viewpoint - Yaoyigou's stock price has increased by 5.12% on January 14, reaching 42.48 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 10.47%, resulting in a total market capitalization of 4.064 billion CNY. The stock has risen for three consecutive days, with a cumulative increase of 14.22% during this period [1] Company Overview - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. is located at 18 Youlian Street, Jin Niu District, Chengdu, Sichuan Province, and was established on April 28, 2007. The company was listed on January 27, 2021. Its main business involves the wholesale and retail of pharmaceutical products in the outpatient market [1] - The revenue composition of the main business is as follows: pharmaceuticals (chemical drugs) account for 99.27%, while other products (supplements) account for 0.73% [1] Shareholder Information - According to data from the top ten circulating shareholders of Yaoyigou, a fund under Nuoan Fund ranks among the top shareholders. The Nuoan Multi-Strategy Mixed A Fund (320016) entered the top ten circulating shareholders in the third quarter, holding 564,000 shares, which represents 0.92% of the circulating shares. It is estimated that the fund has gained approximately 1.1675 million CNY today, with a total floating profit of 2.8369 million CNY during the three-day increase [2] - The Nuoan Multi-Strategy Mixed A Fund (320016) was established on August 9, 2011, with a latest scale of 1.855 billion CNY. Year-to-date returns are 5.21%, ranking 2743 out of 8838 in its category; the one-year return is 88.18%, ranking 316 out of 8089; and since inception, the return is 247.2% [2] - The fund manager of Nuoan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 5 years and 50 days. The total asset scale of the fund under his management is 5.608 billion CNY, with the best fund return during his tenure being 93.39% and the worst being -16.74% [2]

Core Viewpoint - The stock of Luyuan Pharmaceutical (002788) closed at 26.26 yuan on January 13, 2026, reflecting a decrease of 3.74% with a turnover rate of 13.56% and a trading volume of 517,800 lots, amounting to a transaction value of 1.392 billion yuan [1]. Group 1 - The company is committed to providing quality services to upstream and downstream clients in response to the cross-strait social security and medical insurance integration, although specific revenue projections were not disclosed [2]. - The company is adapting its operational strategies in accordance with national medical insurance reforms while ensuring compliance with regulatory requirements [3]. Group 2 - On January 13, the net outflow of institutional funds was 139 million yuan, while retail investors saw a net inflow of 137 million yuan [4][5]. - The trading data indicates a net inflow of 2.5962 million yuan from speculative funds on the same day [5].

Group 1 - The company is actively advancing its digital transformation by leveraging AI to enhance industrial upgrades [1] - The company has completed the privatization deployment of AI computing power and large models, and is implementing a unified AI capability platform [1] - The integration of AI is being applied internally in areas such as operations, risk control, marketing, finance, and logistics, while externally it is enhancing clinical auxiliary diagnosis applications in traditional Chinese medicine and specialized diseases [1]

Core Viewpoint - Luyuan Pharmaceutical (002788) is adapting its business strategies based on market feedback while strictly adhering to regulatory requirements to provide quality services to its upstream and downstream customers [1]. Group 1 - The company is responding to market feedback by adjusting its operational measures [1]. - The company emphasizes compliance with relevant regulatory requirements in its operations [1]. - The focus is on delivering high-quality services to both upstream and downstream clients [1].